Please assess the completion status of the following clinical trial:

Trial Title: House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* A clinical relevant history consistent with house dust mite induced asthma of at least 1 year prior to trial entry.~* Use of an appropriate amount of inhaled corticosteroid for the control of asthma symptoms.~* Documented reversible airway obstruction.~* Suitable level of asthma control.~* FEV1 ≥ 70% of predicted value.~* Positive Skin Prick Test response to Der pte and/or Der far.~* Positive specific IgE against Der pte and/or Der far (≥ IgE Class 2; ≥ 0.70 KU/L).~Key Exclusion Criteria:~* A clinical history of persistent allergic asthma or rhinitis caused by an allergen to which the subject is regularly exposed and sensitised (except house dust mites).~* A clinical history of intermittent allergic asthma or rhinitis if the seasonal allergen is causing symptoms in the period from October to March.~* Any clinically relevant chronic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- ALK HDM AIT 6 DU (Type: EXPERIMENTAL): None
- ALK HDM AIT 12 DU (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).